Final Program
4njPuP
4njPuP
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
398 WEDNESDAY • MAY 18<br />
D88<br />
BEHAVIORAL • CLINICAL<br />
SCIENTIFIC SYMPOSIUM<br />
CME Credits Available: 2.0<br />
THE PATIENT-CENTERED JUGGERNAUT: THE<br />
RIGHT MOVE FOR CLINICAL CARE, POLICY, AND<br />
RESEARCH?<br />
Assemblies on Behavioral Science and Health Services Research;<br />
Critical Care; Thoracic Oncology<br />
1:30 p.m. - 3:30 p.m. MOSCONE CENTER<br />
Room 303/305 (South Building, Esplanade Level)<br />
Target Audience<br />
Clinicians or researchers who incorporate patient centered outcomes in their<br />
practice or research.<br />
Objectives<br />
At the conclusion of this session, the participant will be able to:<br />
• understand the benefits and limitations of patient and family satisfaction as<br />
a quality metric in critical care;<br />
• learn about advantages and disadvantages of shared decision making as a<br />
policy requirement in lung cancer screening;<br />
• determine if the methods to conduct high quality patient engaged research<br />
are available for implementation by researchers.<br />
There is an emerging trend toward incorporating patients' values, opinions and<br />
feedback in both patient care and research. Patient engagement is expected to<br />
address patients’ health care concerns and close the gaps in evidence needed<br />
to improve key outcomes. However, it remains unclear how this process will<br />
actually improve meaningful clinical outcomes and research products. Despite<br />
the difficulties in measuring the benefits and harms of this strategy, patient<br />
centered approaches are being adopted in clinical care, health policy and<br />
research. We will select case examples from key pillars of PCCM to highlight<br />
the current controversies for and against incorporating patient centered<br />
outcomes.<br />
Chairing: D.R. Sullivan, MD, MA, Portland, OR<br />
L.C. Feemster, MD, MSc, Seattle, WA<br />
R.S. Wiener, MD, MPH, Boston, MA<br />
1:30 A Patient’s Perspective<br />
J. Lefferts, San Francisco, CA<br />
1:35 Incorporating Patient Centered Outcomes in Clinical Practice<br />
and Research<br />
S.D. Halpern, MD, PhD, Philadelphia, PA<br />
1:47 PRO: Patient and Family Satisfaction is a Key Quality Metric in<br />
Critical Care<br />
E.K. Kross, MD, Seattle, WA<br />
2:02 CON: Patient and Family Satisfaction is a Key Quality Metric in<br />
Critical Care<br />
G.D. Rubenfeld, MD, MSc, Toronto, Canada<br />
2:17 General Discussion<br />
2:21 CON: Shared Decision Making Improves Outcomes in Lung<br />
Cancer Screening<br />
C.G. Slatore, MD, Portland, OR<br />
2:36 PRO: Shared Decision Making Improves Outcomes in Lung<br />
Cancer Screening<br />
R.S. Wiener, MD, MPH, Boston, MA<br />
2:51 General Discussion<br />
2:55 PRO: We Possess the Methods to Conduct High Quality<br />
Patient Engaged Research<br />
S. Parthasarathy, MD, Tucson, AZ<br />
3:10 CON: We Possess the Methods to Conduct High Quality<br />
Patient Engaged Research<br />
M. Helfand, MD, MS, MPH, Portland, OR<br />
3:25 General Discussion<br />
D89<br />
BASIC • CLINICAL • TRANSLATIONAL<br />
SCIENTIFIC SYMPOSIUM<br />
CME Credits Available: 2.0<br />
NOVEL APPROACHES TO TREAT PULMONARY<br />
INFECTIONS<br />
Assemblies on Allergy, Immunology and Inflammation; Microbiology,<br />
Tuberculosis and Pulmonary Infections; Pediatrics; Respiratory Cell and<br />
Molecular Biology; Respiratory Structure and Function<br />
1:30 p.m. - 3:30 p.m. MOSCONE CENTER<br />
Room 3007/3009 (West Building, Level 3)<br />
Target Audience<br />
Scientists, physician scientists and clinicians working on developing and<br />
utilizing novel therapeutics to treat and prevent pulmonary infections.<br />
Objectives<br />
At the conclusion of this session, the participant will be able to:<br />
• identify novel strategies for treatment of respiratory infection.<br />
• understand how these novel therapies target the pathogen or the host to<br />
promote innate immune clearance.<br />
• recognize and understand the pitfalls and/or challenges present in the<br />
development of such therapies.<br />
Opportunistic bacterial pathogens are a common cause of respiratory infection,<br />
especially in the immune compromised or in hospital settings. Widespread use<br />
of broad spectrum antibiotics has led to the emergence of antibiotic resistance<br />
in a group of respiratory pathogens labeled the ESKAPE pathogens<br />
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,<br />
Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species)<br />
and damaging effects of antibiotics on the gut microbiome. These factors,<br />
coupled with a reduction in the discovery rate of new antimicrobial therapies,<br />
necessitate efforts aimed at identifying novel and potentially pathogen specific<br />
antimicrobial therapeutics. This session will highlight recent discovery of novel<br />
treatment modalities for respiratory infection and exacerbation, including<br />
strategies targeting both the microbe and the host.<br />
Chairing: J.K. Kolls, MD, Pittsburgh, PA<br />
T. Cohen, PhD, Gaithersburg, MD<br />
1:30 Antibodies: A Pathogen Specific Approach to Combating<br />
Respiratory Infection<br />
S. Projan, PhD, Gaithersburg, MD<br />
ATS 2016 • San Francisco